"Today, more than 4 million Americans are infected with hepatitis C and the vast majority do not know it," said Dr. Eugene R. Schiff, Director of the Schiff Center for Liver Diseases, University of Miami School of Medicine, and Vice President of the Chronic Liver Disease Foundation. "We enthusiastically support the CDC's recommendations for broader and more accessible testing for HCV and feel that we are rapidly approaching a time when it will be 'test-and-treat.' Point-of-care testing, in particular, can play a critical role in expanding testing opportunities and facilitating immediate care for those diagnosed with HCV."
The Company's OraQuick® HCV test is the only FDA-approved rapid, point-of-care test for the detection of antibodies to the hepatitis C virus in persons with signs or symptoms of hepatitis and in persons at risk for hepatitis C infection. The test, which utilizes the OraQuick® technology platform, provides results in 20 minutes.
OraQuick® HCV is the centerpiece of numerous rapid HCV testing programs currently being implemented across the nation, including the Check Hep C NYC program, run by The Fund for Public Health in New York, in partnership with the New York City Department of Health & Mental Hygiene Office; as well as other programs in Chicago, Columbus, Honolulu, Houston, Los Angeles, New York City, Washington, D.C. and various other cities.
About OraSure TechnologiesOraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In July 2012, the Company received approval from the U.S. Food and Drug Administration for the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market – making it the first and only rapid OTC HIV test approved in the U.S. In addition, the Company is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.